Nested Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $90M
Overview
Developing small molecule precision oncology drugs against undruggable allosteric targets.
Oncology
Technology Platform
A proprietary platform integrating structural and computational biology to discover and drug allosteric sites on proteins, enabling targeting of historically undruggable cancer targets.
Funding History
1Total raised:$90M
Series A$90M
Opportunities
Potential to create first-in-class therapies for genetically defined cancers with high unmet need.
Risk Factors
High technical risk in validating a novel platform and translating allosteric drug discovery into clinical candidates.
Competitive Landscape
Competes with other precision oncology biotechs and large pharma exploring allostery and protein degradation for difficult targets.